SC 13G: Statement of acquisition of beneficial ownership by individuals-AstraZeneca PLC(9.9%),AstraZeneca AB(9.9%)
6-K: AstraZeneca Strengthens Its Cardiovascular Pipeline with Agreement for a Pre-Clinical Novel Lipid-Lowering Therapy
6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
6-K: Tagrisso Approved in the US for Patients with Unresectable, Stage III EGFR-mutated Lung Cancer
6-K: Fasenra Recommended for Approval in the EU by CHMP for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
6-K: Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR-Positive, HER2-Low or Negative Breast Cancer in TROPION-Breast01 Phase III Trial
6-K: FluMist Approved for Self-Administration in the US
6-K: Fasenra Approved in the Us for Eosinophilic Granulomatosis with Polyangiitis
6-K: Transaction by Person Discharging Managerial Responsibilities
6-K: Total Voting Rights
6-K: Imfinzi Approved in the US for the Treatment of Resectable Non-small Cell Lung Cancer Before and After Surgery
6-K: Total Voting Rights
6-K: Astrazeneca Prices €1.4 Billion Bond Offering
6-K: Fixed-Duration Calquence Plus Venetoclax, With or Without Obinutuzumab, Significantly Improved Progression-Free Survival in 1st-Line Chronic Lymphocytic Leukaemia in AMPLIFY Phase III Trial
6-K: FDA Advisory Committee Reviewed Imfinzi for Treatment of Resectable Non-small Cell Lung Cancer Based on AEGEAN Phase III Trial Results
6-K: H1 and Q2 2024 Results
6-K: Acquisition of Amolyt Pharma Completed
6-K: Total Voting Rights
6-K: Lynparza and Imfinzi Combination Recommended for Approval in the EU by CHMP for Patients with Mismatch Repair Proficient Advanced or Recurrent Endometrial Cancer
11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)
No Data
No Data